Avsnitt av Helleday Laboratory
- Prisregn över Helledaylaboratoriets Sean Rudd
Vår postdoc Sean Rudd har hittills haft en riktigt bra vecka. I onsdags belönades han med priset ”SciLifeLab Highlight of the year 2016″ på SciLifeLab summit här i Solna, och igår kom beskedet att Sean har fått 200 000kr från Alex och Eva…
- A great week so far for Helleday Laboratory postdoc Sean Rudd
Our postdoc fellow Sean Rudd is having a good week so far. On Wednesday he was awarded the ”SciLifeLab Highlight of the year 2016”- prize at the SciLifeLab summit, and yesterday he received 200 000 SEK from the Alex and Eva Wallström…
- Welcome Dr Åsa Rosenquist
A few years ago, when west Africa was plagued by an devastating Ebola outbreak, we tried out our protein inhibitors on the Ebola virus. We were delighted when we realized we’d found a group of substances that not only effectively killed…
- Välkommen Åsa!
När det stora ebolautbrottet skedde för ett par år sedan testade vi våra proteinhämmare för att se om de kunde användas till att döda av ebolavirus. Till vår förvåning hittade vi en substansfamilj som inte bara effektivt dödade av…
- Congratulations Saeed Eshtad, PhD!
The Helleday lab wishes to congratulate Saeed Eshtad on a successful thesis defence on Monday February 13th! Saeeds’s thesis is called “Targeting DNA repair pathways for cancer therapy” and the aim of the thesis was to identify and…
- Grattis Saeed Eshtad!
Ett stort grattis till nyblivne Fil.dr Saeed Eshtad som framgångsrikt disputerade med sin avhandling “ Targeting DNA repair pathways for cancer therapy” den 13 februari. Handledare till Saeed var Thomas Helleday och opponent var professor…
- Our metabolic target MTHFD2 crystal structure now resolved with inhibitor
The MTHFD2 protein is uniquely expressed in cancer and not in normal tissue. Yet, it is required for survival in cancer, but not for normal cells. This makes it a highly interesting target, with the potential of finding compounds that…
- The Helleday Team presents potent MTH1 inhibitor ‘Karonudib’ and experimentally addresses the non-active MTH1 inhibitors.
The Helleday Team proudly presents our new potent MTH1 inhibitor Karonudib, which is 20 times more effective than the previously described TH588 inhibitor, recently published in Annals of Oncology. Karonudib stands for: Karolinska nudt1…
- The drugs of the future will target DNA repair
Keeping up the intact DNA is vital for all organisms, and life as we know of it would not exist. Now, we know it is not black or white, but that DNA damage can also lead to imperfection leading to various diseases. Ageing is an example of…
- Framtidens läkemedel kommer att hämma DNA reparation
[et_pb_section admin_label=”section”][et_pb_row admin_label=”row”][et_pb_column type=”4_4″][et_pb_image admin_label=”Image” src=”http://helleday.org/wp-content/uploads/2016/06/LUX_1010-Version-3.jpg” show_in_lightbox=”off”…
